满￥6666，赠豪华版黑神话悟空
Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 抗生素和抗病毒 囊泡 肿瘤
/
抗感染
G蛋白偶联受体/G蛋白 小分子阳性药 免疫/炎症 功能 外泌体 肿瘤发展和微环境演变
/
CCR
艾滋病病毒 抗病毒
/ Maraviroc

马拉韦罗 /Maraviroc 99%+

货号：A330828 同义名： 马拉维若 / UK-427857 Ambeed 开学季，买赠积分，赢豪礼

Maraviroc is a selective CCR5 antagonist (IC50= 6.4 nM) and displays potent anti-HIV-1 activity.

Maraviroc 化学结构 CAS号：376348-65-1
Maraviroc 化学结构
CAS号：376348-65-1
Maraviroc 3D分子结构
CAS号：376348-65-1
Maraviroc 化学结构 CAS号：376348-65-1
Maraviroc 3D分子结构 CAS号：376348-65-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Maraviroc 纯度/质量文件 产品仅供科研

货号：A330828 标准纯度： 99%+
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell,2024. Ambeed. [ A125712 ]
• Cancer Discov., 2024. Ambeed. [ A285925 ]
• JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
• JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
• EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 CCR ↓ 其他靶点 纯度
Maraviroc ++

MIP-1α, IC50: 3.3 nM

MIP-1β, IC50: 5.2 nM

 		99%+
DAPTA +++

CM235-CCR5, IC50: 0.32 nM

gp120 Bal-CCR5, IC50: 0.06 nM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Maraviroc 生物活性

靶点

  • CCR

    MIP-1α, IC50:3.3 nM

    MIP-1β, IC50:5.2 nM
描述 Maraviroc is a reversible antagonist of C-C chemokine receptor type 5 (CCR5), which inhibits the interaction between CCR5 with the envelop glycoprotein gp120 of human immunodeficiency virus-1 (HIV-1), thus blocking HIV-1 entry into cells[6]. The overall in vitro IC50 of maraviroc ranges from 0.1 to 4.5 nM[7]. Incubation with maraviroc-contained medium at the concentration of 0.1 μM for 48 hours induced CCR5 surface expression on activated T cells. Moreover, 24-hour treatment of 1 μM to 100 μM maraviroc inhibited T cell migration induced by various chemokines. T cell proliferation was also shown to be inhibited after 72-hour incubation with 100 μM maraviroc[8]. A study in female RAG-hu mice showed that 5 mM maraviroc, which was applied into the vaginal vault of mice one hour before viral challenge, fully prevented HIV-1 vaginal transmission[9]. Mice with diet-induced hepatocellular carcinoma showed reduced liver fibrosis, lower levels of liver injury markers, and decreased proliferation index with the treatment of 300 mg/L maraviroc added in drinking water for 16 weeks[10]. A phase 2 trial reported that 300 mg/kg maraviroc twice daily decreased the viral loads by 1.6log10 copies/mL in asymptomatic HIV-1-infected patients[6].

Maraviroc 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
CHO cells Function assay 2 h Displacement of [128I]RANTES from human CCR5 receptor coexpressed with Galphai6 in CHO cells after 2 hrs by scintillation counting, IC50=1.4 nM 20137937
HEK293 cells Function assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay, IC50=17.3 Μm 23241029
HeLa-P4 cells Function assay 20 days Antagonist activity at CCR5 receptor expressed in HeLa-P4 cells co-expressing CD4 assessed as inhibition of infusion to HIV gp120 expressed in CHO-tat10 cells after 20 hrs by cell-cell fusion assay, IC50=0.2 nM 21128663
HOS cells Function assay Antiviral activity against HIV1 Ba-L infected in HOS cells assessed as inhibition of viral infection, IC50=2 nM 19664920

Maraviroc 动物研究

Dose Mice: 10 mg/kg[3] (i.p.); 50 mg/kg[3] (p.o., BID) Rat: 1 mg/kg - 5 mg/kg[4] (i.p.)
Administration i.p., p.o
Pharmacokinetics
Animal Rats[5] Dogs[5]
Dose 1 mg/kg (i.v.)
10 mg/kg (p.o.) 		0.5 mg/kg (i.v.)
2 mg/kg (p.o.)
Administration i.v.
p.o. 		i.v.
p.o.
F 100% (i.v.)
5% (p.o.) 		100% (i.v.)
40% (p.o.)
Vd 6.5 L/kg (i.v.) 4.3 L/kg (i.v.)
T1/2 0.9 h (i.v.) 2.3 h (i.v.)
Tmax 2 min (p.o.) 0.75 min (p.o.)
CL 74 ml/min/kg (i.v.) 21 ml/min/kg (i.v.)
Cmax 55 ng/ml (p.o.) 256 ng/ml (p.o.)

Maraviroc 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02519777 HIV Infections Phase 4 Active, not recruiting November 30, 2020 -
NCT02333045 HIV Not Applicable Terminated(Minimal efficacy of... 展开 >> maraviroc alone was found in preliminary data analysis of another study.) 收起 << - United States, Georgia ... 展开 >> Grady Memorial Hospital Atlanta, Georgia, United States, 30303 Grady Infectious Diseases Clinic (Ponce Clinic) Atlanta, Georgia, United States, 30308 收起 <<
NCT00925756 HIV Infections Phase 4 Completed - United States, California ... 展开 >> University Southern California Los Angeles, California, United States, 90033 University California San Diego San Diego, California, United States, 92103 Harbor-UCLA Torrance, California, United States, 90502 收起 <<

Maraviroc 参考文献

[1]Neff CP, Kurisu T, et al. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One. 2011;6(6):e20209.

[2]Dorr P, Westby M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.

[3]Mencarelli A, Graziosi L, et al. CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Transl Oncol. 2013 Dec 1;6(6):784-93. eCollection 2013 Dec 1.

[4]Nayak SU, Cicalese S, et al. Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist. Brain Behav Immun. 2020 Jan;83:288-292.

[5]UK-427857

[6]Woollard SM, Kanmogne GD. Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther. 2015 Oct 1;9:5447-68.

[7]Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.

[8]Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J Antimicrob Chemother. 2013 Mar;68(3):577-86.

[9]Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One. 2011;6(6):e20209.

[10]Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 2013;8(1):e53992.

Maraviroc 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.73mL

1.95mL

0.97mL

19.47mL

3.89mL

1.95mL

Maraviroc 技术信息

CAS号376348-65-1
分子式C29H41F2N5O
分子量 513.666
别名 马拉维若 ;UK-427857
运输蓝冰
存储条件

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 50 mg/mL(97.34 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 6 mg/mL(11.68 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇
动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 7 mg/mL clear

PO 0.5% CMC-Na 30 mg/mL suspension

Tags: Maraviroc | 376348-65-1 | UK-427857 | UK427857 | UK 427857 | CCR5 Antagonist | GPCR/G Protein | Immunology/Inflammation | Anti-infection | CCR | HIV | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Maraviroc 纯度/质量文件 | Maraviroc 亚型比较 | Maraviroc 生物活性 | Maraviroc 细胞研究 | Maraviroc 动物研究 | Maraviroc 临床数据 | Maraviroc 参考文献 | Maraviroc 实验方案 | Maraviroc 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z